Pharmacovigilance: When to Report Adverse Reactions to Contrast Media
Part of the
book series (MEDRAD)
The main objective of pharmacovigilance is the early detection of new adverse drug reactions. Health care professionals play a key role in safety surveillance, as they are frontline observers if serious and unexpected adverse effects occur. They are obliged to report their observations and suspicions to the regulatory authorities, thereby enabling the authorities to react in an appropriate and timely manner.
KeywordsAdverse Drug Reaction Health Care Professional Medicinal Product Nephrogenic Systemic Fibrosis Adverse Drug Reaction Report
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Dukes G (1985) The effects of drug regulation. A survey based on European studies of drug regulation. MTP Press Limited, LancasterCrossRefGoogle Scholar
Finney DJ (1965) The design and logic of a monitor of drug use. J Chronic Dis 18:77–98PubMedCrossRefGoogle Scholar
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermatopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl 21:1104–1108CrossRefGoogle Scholar
Lenz W (1966) Malformations caused by drugs in pregnancy. Am J Dis Child 112:99–106PubMedGoogle Scholar
Regulation (EU) no. 1235/2010 amending Regulation (EC) 726/2004 and Directive 2010/84/EU amending Directive 2001/83/ECGoogle Scholar
Stenver DI (2008) Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol 66:184–186PubMedCrossRefGoogle Scholar
© Springer-Verlag Berlin Heidelberg 2014